(2R)-5,7,8-trimethyl-2-(12-methyltridecyl)-3,4-dihydro-2H-chromen-6-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (2R)-5,7,8-trimethyl-2-(12-methyltridecyl)-3,4-dihydro-2H-chromen-6-ol
• 化学式: C₂₆H₄₄O₂
• 分子量: 388.6
• InChiKey: NIPSGNOKGHVRLT-HSZRJFAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10
• 重原子数：
  28
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10,14-TRIMETYLPENTADECA-5,9,13-TRIEN-2-ONE OR 6,10,14-TRIMETYLPENTADECA-5,9-DIEN-2-ONE<br/>[FR] (6R,10R)-6,10,14-TRIMÉTHYLPENTADÉCAN-2-ONE PRÉPARÉE À PARTIR DE 6,10,14-TRIMÉTHYLPENTADÉCA-5,9,13-TRIÉN-2-ONE OU DE 6,10,14-TRIMÉTHYLPENTADÉCA-5, 9-DIÉN-2-ONE
  申请人：DSM IP ASSETS BV

  公开号：WO2014096098A1

  公开（公告）日：2014-06-26

  The present invention relates to a process of manufacturing (6R,10R)- 6,10,14-trimetylpentadecan-2-one in a multistep synthesis from a mixture of (5E,9E)-, (5E,9Z)-, (5Z,9E)- and (5Z.9Z)- isomers of 6, 10, 14-trimetylpentadeca- 5,9,13-trien-2-one or 6,10,14-trimetylpentadeca-5,9-dien-2-one. The process is very advantageous in that it forms in an efficient way the desired chiral product from a mixture of stereoisomers of the starting product.

  本发明涉及一种从6,10,14-三甲基十五烷-2-酮的异构体混合物中，通过多步合成制备(6R,10R)-6,10,14-三甲基十五烷-2-酮的方法。该方法非常有利，因为它能够高效地从起始产物的立体异构体混合物中形成所需的手性产物。
• NUTRITIONAL POWDER WITH SPECIFIC ANTIOXIDANTS
  申请人：ABBOTT LABORATORIES

  公开号：US20170202260A1

  公开（公告）日：2017-07-20

  Disclosed herein are nutrient delivery systems that provide a nutritional formula for consumption. The nutrient delivery system includes a pod and a nutritional powder comprising at least one antioxidant. The nutritional powder has improved oxidative qualities such as increased shelf life.
• US9994519B2
  申请人：——

  公开号：US9994519B2

  公开（公告）日：2018-06-12
• [EN] STABLE ORAL CANNABIDIOL COMPOSITIONS<br/>[FR] COMPOSITIONS ORALES STABLES DE CANNABIDIOL
  申请人：[en]CARDIOL THERAPEUTICS INC.

  公开号：WO2022120457A1

  公开（公告）日：2022-06-16

  OF DISCLOSURE Stabilized oral cannabidiol composition comprising cannabidiol (CBD) having a purity of at least 98%. The composition further contains β-caryophyllene (BCP), at least one additional lipophilic solvent (e.g. medium chain triglycerides (MCT)), and at least one additional antioxidant (e.g. α-tocopherol (vitamin E)). The composition is substantially free of THC. The CBD can be synthetic, biosynthetic or of botanical origin. Also disclosed are methods of making and the stabilized oral CBD composition.